Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
暂无分享,去创建一个
Chiara Brignole | Fabio Pastorino | Renato Longhi | Annalisa Pezzolo | Angelo Corti | Michele Cilli | Federica Piccardi | Domenico Ribatti | Theresa M Allen | D. Ribatti | M. Cilli | R. Longhi | A. Corti | T. Allen | A. Pezzolo | F. Pastorino | C. Brignole | D. Marimpietri | G. Pagnan | M. Ponzoni | Daniela Di Paolo | Bice Nico | Danilo Marimpietri | Gabriella Pagnan | Mirco Ponzoni | F. Piccardi | D. Di Paolo | B. Nico
[1] H. Sather,et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. , 1991, The New England journal of medicine.
[2] G. Colombo,et al. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. , 2006, Molecular immunology.
[3] D. Ribatti,et al. Human neuroblastoma cells produce extracellular matrix‐degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo , 1998, International journal of cancer.
[4] H. Kalthoff,et al. An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice. , 2000, The Annals of thoracic surgery.
[5] D. Cheresh,et al. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. , 1984, Cancer research.
[6] Theresa M. Allen,et al. Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.
[7] Y. Barenholz,et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.
[8] J Folkman,et al. Transplacental carcinogenesis by stilbestrol. , 1971, The New England journal of medicine.
[9] Kristian Pietras,et al. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Fulvio Magni,et al. Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.
[11] W. Fiers,et al. Tumor necrosis factor‐α augmented tumor response in B16BL6 melanoma‐bearing mice treated with stealth liposomal doxorubicin (Doxil®) correlates with altered Doxil® pharmacokinetics , 2004, International journal of cancer.
[12] Luigi Naldini,et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.
[13] T. Allen,et al. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. , 2004, Journal of the National Cancer Institute.
[14] E. Moase,et al. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. , 1995, Biochimica et biophysica acta.
[15] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[16] F. Pastorino,et al. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. , 2003, Cancer letters.
[17] P. Wesseling,et al. AMINOPEPTIDASE A IS A CONSTITUENT OF ACTIVATED PERICYTES IN ANGIOGENESIS , 1996, The Journal of pathology.
[18] J. Grandis,et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] D. Ribatti,et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. , 2003, Cancer research.
[20] S. Johnson,et al. Anthracyclines in haematology: preclinical studies, toxicity and delivery systems. , 1997, Blood reviews.
[21] T. Allen. Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.
[22] G. Giaccone,et al. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Erkki Ruoslahti,et al. Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.
[24] L. Ellis,et al. The implications of angiogenesis for the biology and therapy of cancer metastasis , 1994, Cell.
[25] R Pasqualini,et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.
[26] A. Rojiani,et al. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy , 2002, International journal of cancer.
[27] D. Stuart,et al. Targeted delivery of antisense oligonucleotides in cancer. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[28] M. Bednarski,et al. Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.
[29] E. Moase,et al. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. , 2003, Cancer research.
[30] H. Shimada,et al. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. , 1998, Cancer research.
[31] Chiara Brignole,et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. , 2006, Journal of the National Cancer Institute.
[32] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.
[34] W. Wilson,et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) , 2002, Cancer Chemotherapy and Pharmacology.
[35] T. Allen,et al. In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma , 2003, International journal of cancer.
[36] K K Matthay,et al. Molecular biology of neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] Pieter Wesseling,et al. Aminopeptidase A is a functional target in angiogenic blood vessels. , 2004, Cancer cell.
[38] T. Allen,et al. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. , 2001, Biochimica et biophysica acta.
[39] L. Mayer,et al. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] Rong Zhou,et al. Antivascular and antitumor activities of liposome-associated drugs. , 2004, Anticancer research.
[41] Robert S. Kerbel,et al. The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.
[42] B. Calabretta,et al. Delivery of c-myb Antisense Oligodeoxynucleotides to Human Neuroblastoma Cells Via Disialoganglioside GD2-Targeted Immunoliposomes: Antitumor Effects. , 2000, Journal of the National Cancer Institute.
[43] T. Allen,et al. Improved Outcome When B-Cell Lymphoma Is Treated with Combinations of Immunoliposomal Anticancer Drugs Targeted to Both the CD19 and CD20 Epitopes , 2004, Clinical Cancer Research.
[44] Theresa M Allen,et al. Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates , 2005, Clinical Cancer Research.
[45] A Vacca,et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. , 1997, Journal of vascular research.
[46] T. Allen,et al. GD2‐mediated melanoma cell targeting and cytotoxicity of liposome‐entrapped fenretinide , 1999, International journal of cancer.
[47] S. Gillies,et al. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. , 1997, Journal of the National Cancer Institute.
[48] S. Cannistra. Cancer of the ovary. , 1993, The New England journal of medicine.
[49] A. Rademaker,et al. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] V. Pistoia,et al. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. , 1995, Cancer research.